{"filing":{"accession_number":"0001628280-26-038307","cik":"0001357874","ticker":"DTIL","company_name":"PRECISION BIOSCIENCES INC","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"dtil-20260527.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026038307/dtil-20260527.htm"},"events":[{"id":8855,"run_id":7777,"accession_number":"0001628280-26-038307","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Precision Biosciences disclosed late-breaking clinical data from its Phase 1 ELIMINATE-B trial presented at EASL Congress 2026, including new biopsy data demonstrating cccDNA elimination in PBGENE-HBV, establishment of pgRNA as a biomarker, and updated safety profile information. The data directly impacts investor assessment of the company's lead therapeutic candidate and pipeline viability.","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":2066,"accession_number":"0001628280-26-038307","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses new clinical and biopsy data from an ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B, presented at EASL Congress 2026. While the data is material to investors evaluating the company's pipeline progress, the disclosure is structured as a Regulation FD announcement of a webcast and press release rather than a formal earnings release or specific event type. The clinical data announcement would affect a reasonable investor's assessment of the company's therapeutic prospects, warranting materiality classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:39:26.376409+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2067,"accession_number":"0001628280-26-038307","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces late-breaking clinical data from the ELIMINATE-B study for PBGENE-HBV, a lead therapeutic candidate, including new biopsy data demonstrating cccDNA elimination, establishment of pgRNA as a biomarker, and safety profile updates. While this is clinical trial progress rather than a traditional earnings release, M\u0026A activity, or executive change, the data directly impacts investor assessment of the company's pipeline and therapeutic viability. The material nature is evidenced by the company's decision to issue a press release and file an 8-K, and the data addresses efficacy, biomarker validation, and safety—all critical to a biopharmaceutical company's valuation and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:39:26.376409+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2066,"accession_number":"0001628280-26-038307","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses new clinical and biopsy data from an ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B, presented at EASL Congress 2026. While the data is material to investors evaluating the company's pipeline progress, the disclosure is structured as a Regulation FD announcement of a webcast and press release rather than a formal earnings release or specific event type. The clinical data announcement would affect a reasonable investor's assessment of the company's therapeutic prospects, warranting materiality classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:39:26.376409+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-05-27"},{"id":2067,"accession_number":"0001628280-26-038307","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces late-breaking clinical data from the ELIMINATE-B study for PBGENE-HBV, a lead therapeutic candidate, including new biopsy data demonstrating cccDNA elimination, establishment of pgRNA as a biomarker, and safety profile updates. While this is clinical trial progress rather than a traditional earnings release, M\u0026A activity, or executive change, the data directly impacts investor assessment of the company's pipeline and therapeutic viability. The material nature is evidenced by the company's decision to issue a press release and file an 8-K, and the data addresses efficacy, biomarker validation, and safety—all critical to a biopharmaceutical company's valuation and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:39:26.376409+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-05-27"}]}